Evidence map›Paper›PMID 39234956›Full record

ArticleAlzheimer's & dementia : the journal of the Alzheimer's Association2024

Personalizing progressive changes to brain structure in Alzheimer's disease using normative modeling.

Serena Verdi, Saige Rutherford, Charlotte Fraza, Duygu Tosun, Andre Altmann, Lars Lau Raket, Jonathan M Schott, Andre F Marquand, James H Cole, Alzheimer's Disease Neuroimaging Initiative

Abstract read
In one paragraph

Article in Alzheimer's & dementia : the journal of the Alzheimer's Association, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed.

  1. Article
  2. Article
  3. Spatially and temporally progressive hypoperfusion in Alzheimer's disease revealed by normative modeling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2026
    Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Structural similarity networks reveal brain vulnerability in dementia.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Article
  10. Article
  11. Review
  12. Article
  13. Article
  14. Article
  15. Article
  16. Review
  17. Personalizing progressive changes to brain structure in Alzheimer's disease using normative modeling.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2024
    Article
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Serena VerdiCentre for Medical Image Computing, University College London, London, UK.
Saige RutherfordDonders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.
Charlotte FrazaDonders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.
Duygu TosunDepartment of Radiology and Biomedical Imaging, University of California San Francisco, San Francisco, California, USA.
Andre AltmannCentre for Medical Image Computing, University College London, London, UK.
Lars Lau RaketDepartment of Clinical Sciences, Lund University, Malmö, Sweden.
Jonathan M SchottDementia Research Centre, UCL Queen Square Institute of Neurology, London, UK.
Andre F MarquandDonders Centre for Cognitive Neuroimaging, Donders Institute for Brain, Cognition and Behaviour, Radboud University, Nijmegen, the Netherlands.
James H ColeCentre for Medical Image Computing, University College London, London, UK.ORCID 0000-0003-1908-5588
Alzheimer's Disease Neuroimaging Initiative

Funding

Alzheimer's Disease Neuroimaging Initiative - SupplementU01AG024904 · NIA · NORTHERN CALIFORNIA INSTITUTE RES &EDUC · PI WEINER, MICHAEL W · 2004 to 2015
$121.0M
AbbVieADNIaegis of JPNDAgence Nationale de la Recherche ANR-19-JPW2-000Alzheimer's AssociationAlzheimer's Association; Alzheimer's Drug Discovery FoundationAlzheimer's Drug Discovery FoundationAlzheimer's Research UKAlzheimer's Therapeutic Research InstituteAraclon BiotechBioClinica, Inc.BiogenBrain Research UKBristol-Myers Squibb CompanyBritish Heart FoundationCereSpir, Inc.CIHRCogstateDepartment of Health's National Institute for Health ResearchDepartment of Health's National Institute for Health Research funded University College London Hospitals Biomedical Research CentreDOD ADNI W81XWH-12-2-0012Dutch Organization for Scientific ResearchEarly Detection of Alzheimer's Disease SubtypesEisai IncorporatedElan Pharmaceuticals, Inc.Eli Lilly and CompanyEPSRC-funded UCL Centre for Doctoral Training in IntelligentEU Joint Programme-Neurodegenerative Disease ResearchEuroImmunF. Hoffmann-La Roche Ltd.Foundation for the National Institutes of HealthFujirebioGE HealthcareGenentech, Inc.Integrated Imaging in Healthcare EP/S021930/1Italian Ministry of HealthItalian Ministry of Health (MoH)IXICO Ltd.Janssen Alzheimer Immunotherapy Research & Development, LLC.Johnson & Johnson Pharmaceutical Research & Development LL.Laboratory for Neuro ImagingLumosityLundbeckMedical Research CouncilMerck & Co., Inc. Meso Scale Diagnostics, LLCNational Health & Medical Research Council 1191535National Research, Development and Innovation Office 2019-2.1.7-ERA-NET-2020-00008NeuroRx ResearchNeurotrack TechnologiesNIA NIH HHS U01 AG024904NIBIB NIH HHSNIH HHS U01 AG024904Northern California Institute for Research and EducationNovartis Pharmaceuticals CorporationPfizer Inc.Piramal ImagingServierTakeda Pharmaceutical CompanyTransition TherapeuticsUnited Kingdom, Medical Research Council MR/T046422/1University College London Hospitals Biomedical Research CentreUniversity of Southern CaliforniaVIDI 016.156.415Weston Brain InstituteZonMw 733051106
6 · The paper itself

Abstract

introductionNeuroanatomical normative modeling captures individual variability in Alzheimer's disease (AD). Here we used normative modeling to track individuals' disease progression in people with mild cognitive impairment (MCI) and patients with AD.

methodsCortical and subcortical normative models were generated using healthy controls (n ≈ 58k). These models were used to calculate regional z scores in 3233 T1-weighted magnetic resonance imaging time-series scans from 1181 participants. Regions with z scores < -1.96 were classified as outliers mapped on the brain and summarized by total outlier count (tOC).

resultstOC increased in AD and in people with MCI who converted to AD and also correlated with multiple non-imaging markers. Moreover, a higher annual rate of change in tOC increased the risk of progression from MCI to AD. Brain outlier maps identified the hippocampus as having the highest rate of change. DISCUSSION: Individual patients' atrophy rates can be tracked by using regional outlier maps and tOC. HIGHLIGHTS: Neuroanatomical normative modeling was applied to serial Alzheimer's disease (AD) magnetic resonance imaging (MRI) data for the first time. Deviation from the norm (outliers) of cortical thickness or brain volume was computed in 3233 scans. The number of brain-structure outliers increased over time in people with AD. Patterns of change in outliers varied markedly between individual patients with AD. People with mild cognitive impairment whose outliers increased over time had a higher risk of progression from AD.

Indexed as

Alzheimer DiseaseAtrophyBrainCognitive DysfunctionDisease ProgressionMagnetic Resonance ImagingAgedFemaleHumansMaleAlzheimer's diseasedisease progressionlongitudinal serial magnetic resonance imagingmild cognitive impairmentneuroimagingnormative modeling

Identifiers

PMID39234956
PMCPMC11633367

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.